Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective cohort study of PP1M vs oral paliperidone in adolescents with schizophrenia
ChiCTR2400085792Phase 4Recruiting
- Sponsor
- Tianjin Anding Hospital
- Start
- Jun 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paliperidone palmitate and paliperidone in schizophrenia (2 arms), sponsored by Tianjin Anding Hospital. Primary endpoints: PANSS, PSP and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
paliperidone palmitatepaliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR2400085792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085792.